Page last updated: 2024-11-03

pyridinolcarbamate and Adenocarcinoma of Lung

pyridinolcarbamate has been researched along with Adenocarcinoma of Lung in 1 studies

Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)

Adenocarcinoma of Lung: A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Yu, Z1
Peng, Y1
Gao, J1
Zhou, M1
Shi, L1
Zhao, F1
Wang, C1
Tian, X1
Feng, L1
Huo, X1
Zhang, B1
Liu, M1
Fang, D1
Ma, X1

Other Studies

1 other study available for pyridinolcarbamate and Adenocarcinoma of Lung

ArticleYear
The p23 co-chaperone is a succinate-activated COX-2 transcription factor in lung adenocarcinoma tumorigenesis.
    Science advances, 2023, 06-30, Volume: 9, Issue:26

    Topics: Adenocarcinoma of Lung; Carcinogenesis; Cell Transformation, Neoplastic; Cyclooxygenase 2; HSP90 Hea

2023